IP Library Granted Patent US 9,233,085
Granted Patent B1
US 9,233,085 · App. 14/318,245 · Granted Jan 12, 2016

Topical application of AMPK activators for pharmacological prevention of chronic pain

Inventors: Theodore J. Price (Plano, TX); Gregory D. Dussor (Richardson, TX); Dipti Tillu (Tucson, AZ); Bo Lian (Millbrae, CA)
Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
A61K31/155A61K9/0014A61K31/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,085
App. No.
14/318,245
Granted
Jan 12, 2016
Kind
B1
Abstract

A topical composition containing an adenosine monophosphate protein kinase (AMPK) activator and methods of administering the AMPK activator for treating acute pain or preventing the development of chronic pain in a subject. The AMPK activator is resveratrol. A second AMPK activator may also be used. The second AMPK activator is metformin. The topical composition may be administered as a gel, ointment, cream, lotion, suspension, liquid, or transdermal patch.

Claims (5)

1. A method of reducing incision-induced hypersensitivity or incision-induced hyperalgesic priming in a subject, said method comprising administering to the subject a systemic dosage of metformin and a local dosage of resveratrol at or near a surgical incision site, wherein co-treatment with systemic metformin and local resveratrol reduces incision-induced hypersensitivity or incision-induced hyperalgesic priming, wherein the dosage of resveratrol is an individually sub-efficacious dose, and the dosage of metformin is an individually sub-efficacious dose.

2. The method of claim 1 , wherein the dosages of resveratrol and metformin are administered at a time that is between 24 hours before and 24 hours after the surgical incision is made.

3. A method for inhibiting the development of chronic pain due to a surgical incision in a subject, said method comprising administering both a dosage of resveratrol and a dosage of metformin to the subject, wherein co-treatment of both resveratrol and metformin help inhibit the development of chronic pain from the surgical incision, wherein the dosage of resveratrol is an individually sub-efficacious dose, and the dosage of metformin is an individually sub-efficacious dose.

4. The method of claim 3 , wherein the doses of resveratrol and metformin are administered at a time that is between 24 hours before and 24 hours after the surgical incision is made.

5. The method of claim 3 , wherein resveratrol is administered locally to the incision and metformin is administered systemically.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 9, 2014
From: UNIVERSITY OF ARIZONA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033934/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2014
From: PRICE, THEODORE J.; DUSSOR, GREGORY D.; TILLU, DIPTI; LIAN, BO
To: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Reel/Frame 033817/0651 →
Continuity (1)
Provisional Application 61840886 · Jun 28, 2013